New Blood Test Offers Early Detection of Drug-Induced Tissue Damage in Cancer Patients
en-GBde-DEes-ESfr-FR

New Blood Test Offers Early Detection of Drug-Induced Tissue Damage in Cancer Patients


New study introduces a simple blood test to detect early lung damage in cancer patients receiving novel therapy with antibody–drug conjugates (ADCs), which can sometimes cause serious, even fatal, lung disease (ILD). By analyzing specific markers in circulating DNA, this test provides a non-invasive way to monitor patients for lung complications without relying solely on imaging scans. This advancement is important because it could help doctors detect and manage damage sooner, improving safety for patients on powerful cancer drugs and making ongoing monitoring easier and more accessible.

[Hebrew University] – A team of researchers led by Dr. Albert Grinshpun from the Sharett Institute of Oncology at Hadassah-Hebrew University Medical Center and Dr. Ori Fridlich from Center for Liquid Biopsy at the Department of Pediatric Hemato-Oncology, Hadassah-Hebrew University Medical Center have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer patients taking antibody–drug conjugates (ADCs). This breakthrough method aims to offer a safer, simpler way to monitor patients for drug-induced lung disease, potentially reducing the need for frequent scans.

ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies. However, these drugs can sometimes cause interstitial lung disease (ILD)—a serious condition that can lead to significant lung damage if left untreated. This study demonstrates that by analyzing specific markers in blood samples, doctors can spot early signs of lung damage caused by these drugs. This concept is based on the seminal work originated by Prof. Yuval Dor and Ruth Shemer from the Faculty of Medicine, The Hebrew University.

In this study, researchers retrospectively examined blood from patients with metastatic HER2-positive cancers who were treated with Enhertu and a minority of them developed lung damage during Enhertu treatment. By analyzing these samples, the team detected markers of lung damage that matched symptoms confirmed by medical imaging.

“ADCs and other novel cancer therapies are powerful treatments, but monitoring their side effects can be complex,” said Dr. Grinshpun. “This blood test could offer a low-cost, non-invasive way to detect lung damage early on, helping patients get timely care without relying solely on scans.”

This discovery offers a new approach for monitoring lung health in patients taking ADCs, providing a promising, accessible option for early detection and monitoring. The research team aims to develop this method further for broader clinical use.
The research paper titled “Detection of antibody–drug conjugate-induced interstitial lung disease using circulating cell-free DNA” is now available at ESMO Open and can be accessed at https://www.esmoopen.com/article/S2059-7029(24)01485-6/fulltext
DOI: 10.1016/j.esmoop.2024.103715

Researchers:
A. Grinshpun1,2,3, A. Zick1,3, T. Perri3,4, A. Naim1, P. Tarantino5,6, S.M. Tolaney5,6, J. Magenheim7, O. Fridlich8

Institution:
1. Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem
2. Hadassah Cancer Research Institute and Wohl Institute for Translational Medicine, Hadassah-Hebrew University Medical Center, Jerusalem
3. The Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem
4. Department of Gyneco-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
5. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston
6. Harvard Medical School, Boston, USA
7. Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem
8. Center for Liquid Biopsy at the Department of Pediatric Hemato-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Regions: Middle East, Israel
Keywords: Health, Medical, Well being

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Témoignages

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Nous travaillons en étroite collaboration avec...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by DNN Corp Terms Of Use Privacy Statement